Tag: Pfizer

Pfizer's shares have been declining for three years, and the company's forecast for 2026 appears bleak due to significant patent ...

Pfizer (NYSE: PFE) and Merck (NYSE: MRK) have underperformed compared to broader equities in 2023, with both companies reporting lackluster ...

Pfizer (NYSE: PFE) is currently facing investor skepticism due to upcoming patent expirations for three key drugs in 2027 and ...

Palantir has raised its revenue forecast for 2025 following robust quarterly growth, while Pfizer has initiated a second lawsuit against ...

Recent concerns for pharmaceutical companies have centered on President Trump's plans to reduce drug prices and impose tariffs on imports, ...

President Trump announced that Pfizer will lower prescription drug prices for Medicaid and introduced a "TrumpRx" website aimed at offering ...

Pfizer (NYSE: PFE) has signed an agreement with the White House to help Americans access lower prescription drug prices and ...

Robin Phillip, a 45-year-old from Westwego, Louisiana, underwent two craniotomies after being diagnosed with an intracranial meningioma, which she believes ...

Washington — Pfizer has agreed to lower prices on some medications for Medicaid, coinciding with the White House's announcement of ...

The GLP-1 market is dominated by Eli Lilly and Novo Nordisk, but Pfizer is making significant efforts to enter this ...